Italia markets close in 2 hours 16 minutes

FTSE MIB
33.389,94
-317,27(-0,94%)
Dow Jones
39.112,16
-299,05(-0,76%)
Nasdaq
17.717,65
+220,84(+1,26%)
Nikkei 225
39.667,07
+493,92(+1,26%)
Petrolio
80,84
+0,01(+0,01%)
Bitcoin EUR
57.489,36
+236,62(+0,41%)

NBIX Sep 2024 170.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

2,4800

0,0000

(0,00%)

In data: 12:24PM EDT. Mercato aperto.

GlobeNewswire
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat